Pathogen inactivating and nucleic acid stabilization media for microorganism collection and transport
AssigneeBiocept, Inc.
InventorLyle ARNOLD
Life of this patent
Estimating the term…
Abstract
The present disclosure provides pathogen inactivating formulations, and methods of use thereof in collecting, transporting and storing biological samples, as well as preventing degradation of and purifying nucleic acids. The disclosure further provides methods of preparing compositions comprising the pathogen inactivating formulation and a biological sample.
Claims31
A formulation for lysing cells in a biological sample and stabilizing the RNA contained in said cells, comprising a detergent, a metal chelating agent and a buffer, wherein the concentration of the detergent is in the range of about 0.1% to about 3%, wherein the concentration of the metal chelating agent is in the range of about 0.1 mM to about 5.0 mM, wherein the concentration of the buffer is in the range of about 20 mM to about 40 mM and wherein contact of the formulation with a biological sample results in one or more of the following:
- (a) inactivation of a nuclease in the biological sample, (b) inactivation of a pathogenic microbe in the biological sample, (c) disruption of an association of a protein with a nucleic acid in the biological sample, and (d) reduction or prevention of degradation of a nucleic acid in the biological sample, wherein the biological sample is derived from a subject.
2-6. (canceled)
(canceled)
10-11. (canceled)
13-14. (canceled)
16-23. (canceled)
25-27. (canceled)
29-34. (canceled)
(canceled)
38-41. (canceled)
43-45. (canceled)
48-49. (canceled)
A formulation, comprising:
- (a) about 3% sodium lauryl sulfate;
- (b) about 1 mM each of the EDTA and EGTA;
- and (c) about 30 mM of phosphate buffer;
- wherein the formulation has a pH of about 6.7, and wherein the formulation does not comprise guanidinium thiocyanate.
(canceled)
53-63. (canceled)
65-73. (canceled)
75-80. (canceled)
Dependencies are inferred from the claim text.